利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.014 秒)

    ANTIDIURETIC FORMULATION
    1.
    发明申请
    ANTIDIURETIC FORMULATION 审中-公开

    公开(公告)号：US20190282644A1

    公开(公告)日：2019-09-19

    申请号：US16355349

    申请日：2019-03-15

    申请人： Fei SUN

    发明人： Fei SUN

    IPC分类号： A61K36/28 ,  A61K36/57 ,  A61K36/076 ,  A61K36/54 ,  A61K36/884 ,  A61P13/02

    摘要： An exemplary formulation including a specific weight ratio of Atractylodes macrocephala to other certain ingredients surprisingly had an antidiuretic effect which is opposite to what was expected from the common general knowledge. One aspect of such a formulation includes Atractylodes macrocephala; at least one other ingredient that can include at least one of Polyporus umbellatus; Poria cocos; Cinnamomum cassia (twig); and at least one of Alisma orientale and Alisma plantago-aquatica. The formulation can be formed with a weight ratio of Atractylodes macrocephala being greater than 25% with respect to the at least one other ingredient. These formulations may be useful in a method for the treatment of excessive urination, the method including administering an effective amount of a formulation as described herein to a patent in need thereof.

    Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma
    3.
    发明申请
    Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma 审中-公开
    使用重组灵芝免疫调节蛋白（rLZ-8）制备治疗黑色素瘤的药物

    公开(公告)号：US20160129077A1

    公开(公告)日：2016-05-12

    申请号：US14907263

    申请日：2014-06-13

    申请人： Xitian Zhang ,  Fei Sun

    发明人： Xitian Zhang ,  Fei Sun ,  Chongyang Liang

    IPC分类号： A61K38/16

    CPC分类号： A61K38/16

    摘要： A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.

    摘要翻译： 公开了重组灵芝免疫调节蛋白（rLZ-8）在制备治疗黑素瘤药物中的应用。 通过建立原位肿瘤和转移性肿瘤的实验动物模型，研究了rLZ-8的抗肿瘤作用，表明rLZ-8显着抑制黑素瘤原位肿瘤的生长，形成转移瘤 黑色素瘤

    RECOMBINANT GANODERMA LUCIDIUM IMMUNOMODULATORY PROTEIN (rLZ-8) AND USES THEREOF
    4.
    发明申请
    RECOMBINANT GANODERMA LUCIDIUM IMMUNOMODULATORY PROTEIN (rLZ-8) AND USES THEREOF 审中-公开
    重组GANODERMA LUCIDIUM免疫培养基蛋白（rLZ-8）及其用途

    公开(公告)号：US20110009597A1

    公开(公告)日：2011-01-13

    申请号：US12829653

    申请日：2010-07-02

    申请人： Fei SUN ,  Xitian ZHANG

    发明人： Fei SUN ,  Xitian ZHANG

    IPC分类号： C07K14/00

    CPC分类号： C07K14/37 ,  A61K38/00 ,  C07K14/375 ,  Y02A50/483

    摘要： Provided are the use of the recombinant Ganoderma lucidium immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.

    摘要翻译： 提供了重组灵芝免疫调节蛋白（rLZ-8）用于制造用于抗肿瘤，增加白细胞和抑制免疫排斥的药物的组合物，以及包含rLZ-8蛋白质的药物组合物，其中rLZ-8蛋白质被表达 来自毕赤酵母。

    Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof
    5.
    发明申请
    Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof 审中-公开

    公开(公告)号：US20190352345A1

    公开(公告)日：2019-11-21

    申请号：US16462941

    申请日：2018-03-14

    申请人： Xitian Zhang ,  Fei Sun ,  Xin Zhang

    发明人： Fei Sun ,  Chongyang Liang

    IPC分类号： C07K14/375 ,  A61P35/00 ,  A61P35/04

    摘要： Mutants of recombinant immunoregulatory protein of Ganoderma lucidum (rLZ-8) and applications thereof are provided. It is found by the present invention that: an anti-EGFR (epidermal growth factor receptor) domain exists in a structure of the rLZ-8; particularly, the domain through positive potential characteristics thereof induces a killing effect to an abnormal EGFR-expressed tumor. Based on the above scientific discovery, with utilizing computational simulation technology, the mutants of the rLZ-8, having better antitumor effects, are obtained.

    Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof
    6.
    发明申请
    Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof 审中-公开
    甲氧基聚乙二醇丙酸琥珀酰亚胺酯改性重组灵芝免疫调节蛋白，其制备方法及应用

    公开(公告)号：US20150329601A1

    公开(公告)日：2015-11-19

    申请号：US14814356

    申请日：2015-07-30

    申请人： Xitian Zhang ,  Fei Sun

    发明人： Xitian Zhang ,  Fei Sun ,  Chongyang Liang

    IPC分类号： C07K14/37

    CPC分类号： C07K14/37 ,  A61K38/00 ,  A61K38/16 ,  A61K47/60 ,  C07K14/375

    摘要： Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, a preparing method and applications thereof are provided, including: the mPEG-SPA modified rLZ-8; the method for preparing the mPEG-SPA modified rLZ-8 comprising: feeding the rLZ-8 dimer and the mPEG-SPA with the molar ratio of 1:1-1:6 into a 0.1M phosphate buffer with pH 5.0-pH 8.0, and stirring by a magnetic stirrer at a room temperature for 1.0-2.5 h, purifying the product for obtaining a modification product with a purity of 98%; and applications of the mPEG-SPA modified rLZ-8 in preparation of medicine for treating leukopenia due to chemotherapy. Advantages are as follows: the method for preparing the mPEG-SPA modified rLZ-8 is simple, and the product is identical; a half-life of the mPEG-SPA modified rLZ-8 is significantly longer than the half-life of unmodified rLZ-8 (illustrated in the FIG. 2); a minimum effective dosage and time for treating leucopenia are also improved.

    摘要翻译： 提供了甲氧基聚乙二醇琥珀酰亚胺基丙酸酯改性重组灵芝免疫调节蛋白，其制备方法及应用，包括：mPEG-SPA修饰的rLZ-8; 制备mPEG-SPA修饰的rLZ-8的方法包括：将rLZ-8二聚体和mPEG-SPA以1:1-1:6的摩尔比进料到pH 5.0-pH 8.0的0.1M磷酸盐缓冲液中， 并用磁力搅拌器在室温下搅拌1.0-2.5小时，纯化产物，得到纯度为98％的改性产物; 以及mPEG-SPA修饰的rLZ-8在化疗药物治疗白细胞减少症药物中的应用。 优点如下：制备mPEG-SPA改性rLZ-8的方法简单，产品相同; mPEG-SPA修饰的rLZ-8的半衰期明显长于未修饰的rLZ-8（如图2所示）的半衰期; 治疗白细胞减少症的最小有效剂量和时间也得到改善。

    System and methods for performing decoding error detection in a storage device
    7.
    发明授权
    System and methods for performing decoding error detection in a storage device 失效
    用于在存储设备中执行解码错误检测的系统和方法

    公开(公告)号：US08762818B1

    公开(公告)日：2014-06-24

    申请号：US12713520

    申请日：2010-02-26

    申请人： Fei Sun

    发明人： Fei Sun

    IPC分类号： H03M13/00

    CPC分类号： H03M13/617 ,  H03M13/1525 ,  H03M13/1545 ,  H03M13/2906

    摘要： System and methods for performing decoding error detection in a storage device are provided. Data bits of a data polynomial may be retrieved from a storage device. The data bits may be arranged in a first order. Error correction may be performed on the retrieved data bits of the data polynomial to produce an error polynomial based on error correction parity information encoded in the data polynomial. Bits of the error polynomial are arranged in a second order that is reverse to the first order. A first remainder of the error polynomial may be computed based on data bits corresponding to the data polynomial arranged in the second order. An error in the error polynomial may be detected based on the computed first remainder.

    摘要翻译： 提供了用于在存储设备中执行解码错误检测的系统和方法。 可以从存储设备检索数据多项式的数据位。 数据位可以以第一顺序排列。 可以对所检索的数据多项式的数据位执行误差校正，以基于在数据多项式中编码的纠错奇偶校验信息产生误差多项式。 误差多项式的位以与第一级相反的二次排列。 可以基于与以二阶排列的数据多项式相对应的数据位来计算误差多项式的第一余数。 可以基于计算的第一余数来检测错误多项式中的错误。

    Application of recombinant immunoregulatory protein of ganoderma lucidum in preparation of drug for treating focal cerebral ischemia
    10.
    发明申请
    Application of recombinant immunoregulatory protein of ganoderma lucidum in preparation of drug for treating focal cerebral ischemia 审中-公开
    灵芝重组免疫调节蛋白在制备治疗局灶性脑缺血的药物中的应用

    公开(公告)号：US20160199439A1

    公开(公告)日：2016-07-14

    申请号：US14912914

    申请日：2014-06-13

    申请人： Xitian ZHANG ,  Fei SUN

    发明人： Xitian Zhang ,  Fei Sun ,  Chongyang Liang

    IPC分类号： A61K38/16

    CPC分类号： A61K38/168

    摘要： An application of a recombinant immunoregulatory protein of ganoderma lucidum (rLZ-8) expressed by Pichia pastoris in a preparation of a drug for treating focal cerebral ischemia is provided. The rLZ-8 is able to treat a neurological function injury, decrease a neurological severity score caused by a cerebral injury and decrease an ED-1 positive cell number, so as to decrease an inflammatory response and inhibit apoptosis.

    摘要翻译： 提供了由巴斯德毕赤酵母表达的灵芝重组免疫调节蛋白（rLZ-8）在制备治疗局灶性脑缺血的药物中的应用。 rLZ-8能够治疗神经功能损伤，降低脑损伤引起的神经系统严重程度评分，降低ED-1阳性细胞数，减少炎症反应，抑制细胞凋亡。